| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 5g |
|
||
| Other Sizes |
|
Purity: ≥98%
Procainamide HCl (known also as Procainamide hydrochloride; Procanbid; Procan) is an approved anti-arrhythmic drug that is used to treat cardiac arrhythmia by acting as a potent sodium channel blocker, and also a DNA methyltransferase inhibitor. Procainamide hydrochloride is the hydrochloride salt preparation of Procainamide which demonstrates antiarrhythmic effects correlated with blockade of the Na+ channels.
| ln Vitro |
|
||
|---|---|---|---|
| ln Vivo |
|
||
| Animal Protocol |
|
||
| References |
JPharmacol Rep.2016 Jun;68(3):654-61.
|
| Molecular Formula |
C13H22CLN3O
|
|
|---|---|---|
| Molecular Weight |
271.79
|
|
| CAS # |
614-39-1
|
|
| Related CAS # |
Procainamide;51-06-9
|
|
| SMILES |
Cl[H].O=C(C1C([H])=C([H])C(=C([H])C=1[H])N([H])[H])N([H])C([H])([H])C([H])([H])N(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])[H]
|
|
| InChi Key |
ABTXGJFUQRCPNH-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C13H21N3O.ClH/c1-3-16(4-2)10-9-15-13(17)11-5-7-12(14)8-6-11;/h5-8H,3-4,9-10,14H2,1-2H3,(H,15,17);1H
|
|
| Chemical Name |
4-amino-N-[2-(diethylamino)ethyl]benzamide;hydrochloride
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3.25 mg/mL (11.96 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 32.5 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 3.25 mg/mL (11.96 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 32.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 3.25 mg/mL (11.96 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 120 mg/mL (441.52 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6793 mL | 18.3966 mL | 36.7931 mL | |
| 5 mM | 0.7359 mL | 3.6793 mL | 7.3586 mL | |
| 10 mM | 0.3679 mL | 1.8397 mL | 3.6793 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02103088 | Completed | Behavioral: Sexual and urological intervention |
Prostate Cancer | Danish Cancer Society | May 2014 | Not Applicable |
| NCT02739932 | Completed | Psychotic Disorders Depressive Disorder, Major |
University of Calgary | March 2015 | ||
| NCT02575534 | Withdrawn | Drug: Procainamide | Arrhythmias | Evan Adelstein, MD | October 2015 | Not Applicable |
| NCT02114528 | Terminated | Drug: Antiarrhythmic Drug Therapy Procedure: Catheter ablation |
Ventricular Tachycardia Ventricular Arrhythmia |
Ottawa Heart Institute Research Corporation |
October 2014 | Phase 4 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA